First pharmacophoric hypothesis for T-type calcium channel blockers

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 7, 2004, Pages 1605-1611

  Doddareddy, Munikumar Reddy ^a   Jung, Hee Kyung ^a   Lee, Jae Yeol ^a   Lee, Yong Sup ^a   Cho, Yong Seo ^a   Koh, Hun Yeong ^a   Pae, Ae Nim ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

Hypothesis; Pharmacophore; T type calcium channel

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; MIBEFRADIL;

ARTICLE; CATALYST; EMBRYO; FIBROBLAST; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; KIDNEY CELL; MODEL; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CELL DIVISION; CELL LINE; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1542404528     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.01.034     Document Type: Article

References (20)

1. Opie, L.H; Frishman, W.H; Thadani, U. Calcium channel antagonists (calcium entry blockers). In: Opie, L.H, editor. Drugs for the Heart. 4th ed. Philadelphia: WB Saunders; 1994 p 50.
2. Abernethy D.R., Schwartz J.B. N. Engl. J. Med. 341:1999;1447.
3. Thadani U. Curr. Opin. Cardiol. 14:1999;349.
4. Asirvatham S., Sebastian C., Thadani U. Drug Safety. 19:1998;23.
5. Triggle D.J. J. Hypertens. 15:1997;9.
6. Portegies M.C., Schmitt R., Kraaij C.J., Braat S.H.J.G., Gassner A., Hagemeijer F., Ponzenel H., Prager G., Viersma J.W., VanderWall E.E., Kleinbloesem C.H., Lie K.I. J. Cardiovasc. Pharmacol. 18:1991;746.
7. Cremers B., Flesch M., Sudkamp M., Bohm M. J. Cardiovasc. Pharmacol. 29:1997;692.
8. Ertel S.I., Ertel E.A., Clozel J.P. Cardiovasc. Drugs Ther. 11:1997;723.
9. Mishra S.K., Hermsmeyer K. Circ. Res. 75:1994;144.
10. Benardeau, A.; Ertel, E. Selective block of myocardial T-type calcium channels by mibefradil: A comparison with the 1,4-dihydropyridine,amlodipine, Clozel, J. P., Nargeot, J. Tsien, R. W. (Eds.). pp 386-394, Adis international chester, UK 1997.
11. Kobrin I., Bieska G., Charlon V., Lindberg E., Pordy R. Cardiology. 89:1998;23.
12. Schmassmann-Suhijar D., Bullingham R., Gasser R., Schmutz J., Haefeli W.E. Lancet. 351:1998;1929.
13. Mullins M.E., Horowitz B.Z., Linden D.H., Smith G.W., Norton R.L., Stump J. JAMA. 280:1998;157.
14. SoRelle R. Circulation. 98:1998;831.
15. Reimer K.A., Califf R.M. Circulation. 99:1999;198.
16. CATALYST version 4.8 software; ACCELRYS Inc:2001.
17. Compounds 1a-1c; Bioorg. Med. Chem. manuscript in preparation.
18. Compounds 2a-2d; Bioorg. Med. Chem. Lett., submitted for publication.
19. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. J. Comput. Chem. 4:1983;187.
20. Smellie A., Teig S.L., Towbin P. J. Comput. Chem. 16:1995;171.